New guidelines help reduce glucocorticoid doses in classic CAH patients using CRENESSITY

Neurocrine Biosciences published expert recommendations for safely reducing glucocorticoid doses in patients with classic congenital adrenal hyperplasia (CAH) treated with CRENESSITY (crinecerfont). These guidelines, appearing in The Journal of Clinical Endocrinology & Metabolism, address the need for practical advice as CRENESSITY use grows in both children and adults. CRENESSITY helps lower excess androgen production, allowing patients to shift toward more natural glucocorticoid dosing while maintaining necessary cortisol replacement. This advancement supports better management of CAH treatment, potentially improving patient outcomes.